Okan Akar

Mr. Okan Akar

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Biochimie
Verified
Journal Article
Closed access
MEMerve Erkisa
Merve Erkisa
SASeyma Aydinlik
Seyma Aydinlik
BCBuse Cevatemre
Buse Cevatemre
NANazlihan Aztopal
Nazlihan Aztopal
OAOkan Akar
Okan Akar
EUEngin Ulukaya
Engin Ulukaya

5 August 2019 in TURKISH JOURNAL OF BIOLOGY
Verified
Journal Article
Open access
Didem KarakasDidem Karakas
Didem Karakas
OAOkan Akar
Okan Akar
ZGZeliha Gökmen
Zeliha Gökmen
Nahide Gülşah DenizNahide Gülşah Deniz
Nahide Gülşah Deniz
EUEngin Ulukaya
Engin Ulukaya
Breast cancer is the most-diagnosed cancer type among women. The triple-negative subtype is an especially aggressive type of breast cancer. Although chemotherapy is almost the only option for the treatment of triple-negative breast cancer (TNBC), currently used chemotherapeutics are not effective enough, considering the poor survival rate of patients. Therefore, novel compounds need to be developed to improve survival rates. It has been known that quinonic compounds, which are found in nature, have antibacterial, antifungal, and antitumorigenic properties. Naphthoquinones are members of the quinone family and are widely used in research due to their promising properties. In this study, we evaluated the cytotoxic activity of a novel naphthoquinone-derived compound (1,4-naphthoquinone (1,4-NQ)) against two different breast cancer cells: a hormone-responsive cell line (MCF-7) and a triple-negative cell line (MDA-MB-231). As a result, 1,4-NQ decreased cell viability in both tested cell lines in a dose-dependent manner. Increased apoptotic markers (presence of pyknotic nuclei, annexin-V positivity, caspase 3/7 activity, and decreased mitochondrial membrane potential) and DNA damage were especially observed in MDA-MB-231 cells after treatment with the compound. Considering the promising cytotoxic effect of the compound, 1,4-NQ needs further evaluation as a potential candidate for the treatment of TNBC.

1 December 2019 in Prostate International
Verified
Journal Article
Open access
EAElif Damla Arisan
Elif Damla Arisan
OAOkan Akar
Okan Akar
OROzge Rencuzogullari
Ozge Rencuzogullari
PYPinar Obakan Yerlikaya
Pinar Obakan Yerlikaya
AGAjda Coker Gurkan
Ajda Coker Gurkan
NUNarcin Palavan Unsal
Narcin Palavan Unsal
Prostate cancer is the most common type of cancer among men. Studies showed that the regular use of nonsteroidal antiinflammatory drugs might reduce disease progression risk for prostate cancer patients with prostate cancer. We evaluated the effects of ectopic expression of p53 on the biological functions of ibuprofen and diclofenac. For this purpose, We investigated cell death decision pathways related to survival and aggressive cellular phenotypes such as extrinsic/intrinsic apoptosis decision, Protein Kinase B/ Forkhead box O (AKT/FoxO) axis, mitogen-activated protein kinases (MAPKs), reactive oxygen species (ROS) generation, and EMT (epithelial mesenchymal transition) in wild type and p53 + PC3 prostate cancer cells. Ibuprofen (1 mM) and diclofenac (250 μM) effectively induced cell cycle arrest and led to apoptosis via modulating both extrinsic and intrinsic pathways. However, diclofenac was the only drug to generate ROS intermediates. Diclofenac triggered a typical EMT process with downregulated E-cadherin and upregulated N-cadherin, vimentin, and Snail in PC3 cells, regardless of p53 expression. In conclusion, although both drugs are effective on cell death mechanism, only diclofenac caused EMT because of increased ROS generation independent of p53. On the other hand, ibuprofen could inhibit metastasis via upregulating E-cadherin. The biological targets of both nonsteroidal antiinflammatory drugs are different to highlight their role in cell survival and death axis.

12 March 2020 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
IYIsmail Yılmaz
Ismail Yılmaz
OAOkan Akar
Okan Akar
MEMerve Erkisa
Merve Erkisa
SSSelin Selvi
Selin Selvi
AŞAbdurrahman Şengül
Abdurrahman Şengül
EUEngin Ulukaya
Engin Ulukaya

19 January 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
Didem KarakasDidem Karakas
Didem Karakas
MEMerve Erkisa
Merve Erkisa
OAOkan Akar
Okan Akar
GAGizem Akman
Gizem Akman
ESEzgi Yudum Senol
Ezgi Yudum Senol
EUEngin Ulukaya
Engin Ulukaya
Pancreatic cancer (PaCa) characteristically has a dense tumor microenvironment, which results in poor patient prognosis. Pancreatic stellate cells (PSCs) are the most abundant cells in the PaCa microenvironment and the principal source of collagen. Periostin, a matricellular protein, is produced specifically by PSCs and promotes the aggressiveness of PaCa cells by facilitating extracellular collagen assembly. Here, we aimed to decrease extracellular collagen assembly by suppressing periostin, thereby increasing the cytotoxic activity of natural killer (NK) cells. Periostin expression was suppressed in PSCs (called PSC-P) using CRISPR-Cas9. PaCa cells (BxPC-3) were co-cultured with PSC and PSC-P cells in a 3D environment to form tumor spheroids mimicking the tumor microenvironment. The extracellular collagen production of spheroids was evaluated by Masson’s trichrome staining. The cytotoxic activity of NK-92 cells was analyzed by flow cytometry and confocal microscopy via CD107a staining. Cell death in BxPC-3 cells was evaluated by measuring Annexin-V and PI positivity using flow cytometry. As a result, periostin suppression decreased extracellular collagen and increased the infiltration of NK-92 cells into spheroids, and induced cell death in PaCa cells. In conclusion, we suggest that periostin might be a therapeutic target for PaCa and further analysis is warranted using in vivo models for proof-of-concept.

5 March 2024 in Applied Organometallic Chemistry
Verified
Journal Article
Closed access
PDF file
CICeyda Icsel
Ceyda Icsel
VYVeysel T. Yilmaz
Veysel T. Yilmaz
MAMuhittin Aygun
Muhittin Aygun
MEMerve Erkisa
Merve Erkisa
EUEngin Ulukaya
Engin Ulukaya
OAOkan Akar
Okan Akar